Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-10-16
2008-11-11
Gitomer, Ralph (Department: 1657)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S885000, C435S007240
Reexamination Certificate
active
07449452
ABSTRACT:
The ability of a polysaccharide to act as an immunostimulant may be assessed by comparing the degree of binding of a detection reagent, which contains a fluorescence-labeled version of the polysaccharide, with the binding of a reference reagent, which contains a fluorescence-labeled version of a different polysaccharide. The ability of a polysaccharide to act as an immunostimulant may also be assessed by comparing the degree of binding of a detection reagent, which contains a fluorescence-labeled version of the polysaccharide, with the binding of a different type of reference reagent, which contains both the same fluorescence-labeled version of the polysaccharide and an unlabelled version of the same polysaccharide.
REFERENCES:
patent: 5106616 (1992-04-01), McAnalley et al.
patent: 6956120 (2005-10-01), Ikewaki et al.
patent: 2006/0160766 (2006-07-01), Cheung
patent: 04-024555 (1992-01-01), None
patent: 04-346791 (1992-12-01), None
Suga T., et al., “Antitumor Activity of Lentinan in Murine Syngeneic and Autochthonous Hosts and Its Suppressive Effect on 3-Methylcholantherene-induced Carcinogenesis”,Cancer Research, Nov. 1984, vol. 44, pp. 5132-5137.
50thAnnual Mtg. Proc. Jpn., Cancer Assoc. , 1991, pp. 259.
Vetvicka V., et al. “Soluble β-Glucan Polysaccharide Binding to the Lectin Site of Neutrophil or Natural Killer Cell Complement Receptor Type 3 (CD11b/CD18) Generates a Primed State of the Receptor Capable of Mediating Cytotoxicity of IC3b-Opsonized Target Cells”,J. Clin Invest, Jul. 1996, vol. 98, No. 1, pp. 50-61.
Brown G., et al., “Dectin-1 Is A Major β-Glucan Receptor On Macrophages”,J. Exp. Med, Aug. 5, 2002, vol. 196, No. 3, pp. 407-412.
Oka M. et al., “In Vitro and In Vivo Analysis of Human Leukocyte Binding by the Antitumor Polysaccharide, Lentinan”, Int. J. Immunopharmac., vol. 18, No. 3, pp. 211-216, (1996).
Allendorf, Daniel J., et al., “Macrophages shuttle orally administered beta-glucan to potentiate the CR3-dependent tumoricidal effects of monoclonal antibodies in mouse tumor models”, Faseb Journal, Fed. of American Soc. For Experimental Biology, Bethesda, MD, US, vol. 17, No. 7, May 10, 2003.
Allendorf, Daniel J., et al., “orally administered beta-glucan functions via anti-tumor mAbs and the complement system to recruit CR3+ neutrophils and macrophages the produce tumor regression and tumor-free survival”, Molecular Immunology, Elmsford, NY, US, vol. 40, No. 2-4, Sep. 6, 2003.
Kougias, Panagiotis, et al., “Normal human fibroblasts express pattern recognition receptors for funal (1->3)-beta-D-glucans”, Infection and Immunity, vol. 69, No. 6, Jun. 2001.
Murata Masahiro
Suga Tetsuya
Suga Yasuyo
Ajinomoto Co. Inc.
Gitomer Ralph
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Method for estimating immunostimulant activity of a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for estimating immunostimulant activity of a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for estimating immunostimulant activity of a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4037531